vaccin
industri
compos
compani
engag
follow
activ
research
includ
perform
industri
biotech
develop
manufactur
sale
market
distribut
vaccin
receiv
revenu
chiefli
sale
vaccin
product
expect
thereof
vaccin
industri
rel
small
compar
pharmaceut
industri
grow
estim
total
infecti
diseas
vaccin
sale
billion
worldwid
expect
grow
billion
although
compon
vaccin
industri
found
countri
worldwid
larg
vaccin
compani
primarili
usor
europeanbas
domin
share
vaccin
busi
revenu
basi
region
compani
gradual
grow
market
share
dose
basi
tabl
past
year
vaccin
busi
former
laggard
pharmaceut
busi
shown
remark
growth
power
new
innov
vaccin
coupl
superior
price
strategi
fig
specif
contribut
spectacular
growth
varicella
hepat
pneumococc
conjug
shingl
rotaviru
meningococc
conjug
c
w
human
papillomaviru
hpv
vaccin
well
myriad
combin
vaccin
project
growth
may
plateau
earli
unless
vaccin
industri
continu
introduc
new
innov
product
target
diseas
impact
western
world
sustain
growth
challeng
dwindl
number
highvalu
vaccin
target
biolog
protect
well
understood
see
tabl
vaccin
busi
capitalintens
busi
requir
consider
ongo
invest
manufactur
asset
facil
peopl
maintain
complianc
everincreas
regulatori
direct
recent
departur
baxter
novarti
vaccin
industri
omin
sign
reflect
continu
financi
pressur
remain
four
major
vaccin
maker
consolid
busi
like
addit
new
allianc
form
big
four
manufactur
emerg
compani
india
china
brazil
take
advantag
increas
immun
rate
countri
well
growth
privat
market
unit
state
extraordinarili
success
vaccin
research
develop
r
past
year
new
vaccin
approv
worldwid
develop
unit
state
approxim
new
vaccin
approv
unit
state
sinc
combin
exist
vaccin
introduc
simplifi
pediatr
vaccin
result
wider
adopt
acellular
pertussi
vaccin
polyval
pneumococc
conjug
vaccin
infant
introduc
wyeth
subsidiari
pfizer
wide
adopt
made
pfizer
major
forc
vaccin
busi
sinc
sever
new
vaccin
licens
includ
combin
measl
mump
rubella
mmr
varicella
well
new
vaccin
rotaviru
herp
zoster
hpv
meningococcu
influenza
other
hpv
vaccin
develop
merck
glaxosmithklin
significantli
expand
field
adolesc
vaccin
confirm
market
accept
premium
price
last
year
vaccin
industri
unit
state
europ
consider
improv
reliabl
supplier
chronic
shortag
thing
past
turnaround
primarili
achiev
modern
vaccin
manufactur
distribut
infrastructur
support
fund
profit
vaccin
busi
center
diseas
control
prevent
cdc
stockpil
pediatr
vaccin
allevi
concern
critic
shortag
case
suppli
interrupt
industri
vulner
depend
singlesourc
vaccin
continu
unresolv
concern
regul
industri
must
proactiv
develop
solut
critic
challeng
avoid
futur
public
health
crisi
result
vaccin
shortag
prolong
suppli
interrupt
vaccin
develop
difficult
complex
highli
riski
costli
includ
clinic
develop
process
develop
assay
develop
risk
high
vaccin
candid
fail
preclin
earli
clinic
develop
less
vaccin
candid
enter
phase
ii
achiev
licensur
high
failur
rate
result
varieti
reason
fulli
understand
biolog
protect
lack
good
anim
model
predict
vaccin
behavior
human
unpredict
human
immun
system
reaction
antigen
relat
immunogen
safeti
unpredict
impact
combin
multipl
compon
vaccin
vaccin
develop
requir
strong
project
manag
system
control
requisit
skill
set
among
scientist
engin
key
strateg
document
guid
stakehold
vaccin
develop
target
product
profil
tpp
tpp
summar
desir
characterist
featur
product
develop
key
attribut
product
provid
competit
advantag
final
toplin
roadmap
nonclin
clinic
studi
requir
evalu
product
efficaci
safeti
target
popul
welldefin
tpp
provid
stakehold
includ
research
process
develop
manufactur
clinic
regulatori
senior
manag
clear
statement
desir
outcom
product
develop
program
process
develop
involv
make
prepar
test
vaccin
satisfi
regulatori
requir
clinic
test
includ
clinic
lot
preclin
toxicolog
test
analyt
assess
final
scaleup
method
lead
consist
manufactur
process
onetenth
full
scale
usual
three
consecut
lot
test
clinic
immunogen
assay
develop
involv
definit
specif
method
test
puriti
raw
materi
stabil
potenc
vaccin
product
immunolog
criteria
predict
vaccin
efficaci
gonogo
decis
must
made
stage
clinic
process
develop
vaccin
industri
r
gordon
dougla
vijay
b
samant
must
data
driven
clinic
process
assay
develop
task
must
close
integr
clinic
develop
involv
studi
effect
vaccin
patient
safeti
immunogen
efficaci
stage
process
phase
earli
safeti
immunogen
small
number
phase
safeti
dose
rang
immunogen
individu
sometim
phase
nonlicensur
proofofconcept
trial
efficaci
phase
safeti
efficaci
trial
permit
licensur
gener
requir
thousand
subject
process
broadli
divid
two
categori
bulk
manufactur
finish
oper
bulk
manufactur
includ
cell
cultur
andor
fermentationbas
manufactur
follow
varieti
separ
process
purifi
vaccin
finish
oper
includ
formul
adjuvantstabil
follow
vial
syring
fill
includ
lyophil
case
live
viral
vaccin
follow
label
packag
control
storag
process
develop
may
costli
clinic
develop
critic
import
overal
success
vaccin
develop
program
develop
proce
toward
licensur
cost
escal
clinic
studi
becom
larger
manufactur
scale
facil
must
built
postlicensur
studi
safeti
efficaci
phase
vaccin
essenti
repres
larg
addit
cost
import
note
unlik
pharmaceut
vaccin
pass
earli
proofofconcept
studi
human
high
probabl
achiev
licensur
clinic
activ
visibl
bioprocess
develop
clearli
drive
gonogo
decis
direct
progress
two
interwoven
ratelimit
step
must
done
concert
first
stage
vaccin
develop
involv
accept
candid
basic
research
laboratori
develop
smallscal
process
formul
make
materi
phase
studi
analyt
releas
assay
preclin
toxicolog
immunolog
assay
evalu
clinic
respons
investig
new
drug
ind
file
welldesign
phase
iiia
studi
second
step
complet
definit
product
process
prior
initi
phase
ii
doserang
studi
may
take
year
product
definit
includ
method
synthesisbioprocess
step
number
compon
stabilityformul
stabil
releas
raw
materi
assay
must
place
immunolog
assay
must
establish
support
doserang
studi
regulatori
plan
vaccin
process
product
submiss
must
written
third
step
defin
clinic
dose
arriv
appropri
manufactur
scale
may
take
year
result
identif
manufactur
fill
releas
clinicalgrad
vaccineusu
pilot
plantdemonstr
safeti
dose
respons
phase
ii
clinic
studi
valid
critic
assay
support
phase
iii
clinic
studi
consist
lot
manufactur
abil
produc
three
consecut
productionscal
lot
meet
product
specif
base
valid
analyt
method
complet
technolog
transfer
final
site
materi
manufactur
commerci
factori
especi
difficult
immun
studi
highli
reproduc
case
cellular
immun
assay
decis
pose
larg
financi
risk
product
develop
fail
requir
access
larg
amount
capit
attribut
usual
restrict
larg
pharmaceut
compani
estim
cost
develop
new
drug
vaccin
risen
million
million
billion
estim
take
account
cost
includ
r
cost
product
fail
postlicensur
clinic
studi
improv
manufactur
process
approxim
cost
construct
remaind
cost
capit
interest
number
debat
other
estim
million
million
howev
higher
estim
valid
two
way
first
number
new
vaccin
brought
licensur
annual
compani
industri
small
compar
product
correl
r
expenditur
million
million
new
product
thu
compani
spend
million
annual
vaccin
r
one
might
expect
one
new
product
everi
year
appear
hold
true
second
biotechnolog
compani
focus
one
vaccin
success
brought
market
spent
million
million
r
exemplifi
develop
live
attenu
influenza
vaccin
aviron
medimmun
summari
vaccin
develop
concept
licensur
lengthi
process
illustr
timelin
current
licens
vaccin
tabl
understand
predomin
role
major
pharmaceut
compani
develop
vaccin
one
must
examin
role
vaccin
develop
compani
relat
manufactur
fullscal
lot
includ
process
analyt
procedur
vaccin
target
anim
studi
predict
efficaci
human
hiv
malaria
tuberculosi
tb
small
phase
iib
proofofconcept
studi
base
adapt
clinic
trial
design
may
use
gain
confid
commit
signific
resourc
process
develop
analyt
develop
factori
construct
gener
analyt
releas
assay
particularli
difficult
develop
case
vaccin
consid
wellcharacter
biolog
regulatori
agenc
releas
assay
initi
involv
function
potenc
assay
anim
immunogen
prior
accept
robust
precis
vitro
assay
correl
function
potenc
assay
gener
variabl
biolog
assay
major
hurdl
achiev
process
scaleup
manufactur
consist
fourth
stage
complet
phase
iii
pivot
clinic
studi
correspond
consist
lot
studi
requir
year
key
success
phase
iii
clinic
studi
accur
estim
sampl
size
base
diseas
incid
low
dropout
rate
precis
clinic
end
point
definit
relat
futur
label
claim
rigor
data
manag
highest
standard
addit
clinic
studi
scaleup
manufactur
consist
lot
includ
transfer
facil
assay
facil
valid
demonstr
consist
realtim
stabil
need
support
adequ
shelflif
claim
final
stage
biolog
licens
applic
bla
prepar
licensur
vaccin
launch
requir
year
thu
total
elaps
time
develop
year
assum
activ
proceed
plan
manufactur
plant
expens
construct
rang
million
million
depend
size
dose
requir
manufactur
complex
addit
expenditur
approxim
cost
clean
process
valid
activ
requir
current
good
manufactur
practic
regul
except
vaccin
requir
differ
plant
uniqu
manufactur
requir
regulatori
difficulti
associ
chang
differ
product
process
scalabl
bacteri
yeast
ferment
increas
size
manufactur
unit
ie
ferment
greatli
increas
yield
unit
cost
decreas
volum
increas
manufactur
process
exampl
depend
viral
growth
embryon
hen
egg
cell
line
scalabl
addit
plant
modul
within
plant
must
built
increas
throughput
unit
cost
appreci
decreas
volum
increas
despit
complex
bulk
vaccin
manufactur
year
postproduct
launch
fulli
burden
bulk
cost
product
older
vaccin
declin
littl
per
dose
signific
element
product
cost
primarili
driven
activ
relat
fill
vial
packag
tabl
establish
vaccin
limit
number
supplier
gener
high
profit
margin
product
life
cycl
commit
build
plant
must
made
earli
year
expect
licensur
includ
finish
good
inventori
buildup
expedit
product
market
otherwis
gap
year
licensur
product
launch
occur
furthermor
far
better
produc
consist
lot
final
vaccin
product
factori
demonstr
abil
manufactur
vaccin
reliabl
use
lot
phase
iii
efficaci
trial
otherwis
immun
studi
requir
bridg
product
use
efficaci
trial
bioshield
procur
advanc
medic
countermeasur
biolog
well
threat
success
develop
medic
countermeasur
smallpox
anthrax
botulinum
toxin
addit
barda
fund
varieti
earli
stage
novel
vaccin
approach
pandem
influenza
barda
essenti
intend
overlap
close
gap
nihfund
preclin
initi
phase
trial
advanc
project
bioshield
program
late
stage
phase
iii
licensur
stage
develop
us
agenc
intern
develop
usaid
support
limit
r
target
toward
vaccin
potenti
greatest
impact
children
younger
age
year
develop
countri
center
biolog
evalu
research
cber
divis
us
food
drug
administr
fda
respons
licens
new
vaccin
cber
establish
standard
manufactur
process
facil
preand
postlicens
clinic
studi
ensur
licens
vaccin
safe
effect
see
tabl
standard
profound
partner
rel
contribut
variou
partner
delic
fabric
vaccin
r
shown
tabl
sever
branch
us
govern
play
major
role
vaccin
r
us
nation
institut
health
nih
major
fund
sourc
via
intramur
extramur
larg
academ
program
fundament
research
eg
genebas
vaccin
tcell
memori
studi
direct
research
pathogen
eg
hiv
may
lead
new
vaccin
candid
nih
vaccin
trial
network
increas
role
clinic
develop
domest
intern
addit
dale
betti
bumper
vaccin
research
center
nih
establish
primarili
pursu
develop
hiv
vaccin
center
diseas
control
prevent
cdc
primari
govern
agenc
respons
epidemiolog
monitor
diseas
trend
cdc
conduct
diseas
surveil
epidemiolog
studi
ascertain
preval
incid
specif
diseas
inform
provid
rational
priorit
vaccin
develop
studi
cdc
perform
addit
studi
conduct
vaccin
compani
phase
iv
studi
advisori
committe
immun
practic
acip
cdc
recommend
usag
vaccin
respons
public
purchas
directli
vaccin
children
program
approxim
indirectli
feder
state
local
govern
purchas
approxim
togeth
total
approxim
childhood
vaccin
unit
state
therebi
play
major
role
determin
demand
potenti
profit
associ
vaccin
profession
organ
american
academi
pediatr
american
academi
famili
physician
also
make
recommend
vaccin
usag
feder
vaccin
program
adult
although
medicar
reimburs
influenza
pneumococc
conjug
vaccin
histor
mani
adult
privat
insur
cover
immun
howev
afford
care
act
requir
health
plan
cover
vaccin
recommend
acip
prior
septemb
copay
costshar
requir
servic
deliv
innetwork
provid
depart
defens
dod
target
vaccin
r
help
perform
mission
protect
deploy
impact
natur
direct
vaccin
develop
cost
addit
cber
maintain
strong
research
base
intern
better
posit
evalu
data
variou
studi
cber
remain
premier
vaccin
regulatori
agenc
world
nongovernment
organ
ngo
play
increas
role
vaccin
research
bill
melinda
gate
foundat
support
sever
organ
includ
intern
aid
vaccin
initi
malaria
vaccin
initi
aera
dedic
develop
tb
vaccin
other
signific
fund
develop
vaccin
would
greatest
impact
diseas
develop
countri
addit
relat
organ
program
appropri
technolog
health
path
nonprofit
group
forg
privat
sector
partnership
develop
vaccin
technolog
suitabl
develop
world
product
develop
partnership
organ
pdp
essenti
notforprofit
biotech
compani
bring
togeth
special
knowledg
anim
model
immunolog
assay
field
site
vaccin
test
well
earli
capit
invest
reduc
scientif
technic
risk
opportun
cost
financi
risk
biotech
larg
pharma
industri
partner
also
provid
opportun
valid
novel
vaccin
technolog
platform
role
larg
fullservic
vaccin
compani
limit
basic
research
signific
amount
target
research
regard
specif
organ
preponder
activ
clinic
process
develop
suffici
personnel
expertis
process
develop
chemic
engin
resid
almost
exclus
compani
resourc
develop
clinic
develop
satisfi
fda
standard
also
done
mostli
larg
compani
perform
academia
contract
research
organ
personnel
expertis
clinic
research
regulatori
affair
data
manag
statist
project
manag
requir
disciplin
also
exist
within
larg
compani
perhap
importantli
manag
structur
make
rapid
gonogo
decis
requir
minim
risk
assess
effici
vaccin
develop
mani
smaller
organ
often
refer
biotechnolog
compani
engag
vaccin
research
often
start
univers
scientist
support
ventur
capitalist
capabl
basic
research
vaccin
idea
earli
stage
usual
limit
capac
process
develop
manufactur
clinic
develop
none
distribut
sale
market
research
result
favor
capac
process
engin
clinic
studi
manufactur
must
enhanc
obtain
partner
larg
cost
ad
new
capac
expertis
mani
biotech
compani
advanc
product
develop
opt
partner
larg
fullscal
compani
although
small
compani
claim
engag
vaccin
r
dozen
consid
major
activ
medimmun
made
market
close
market
licens
product
technolog
platform
larger
compani
complet
develop
yield
new
vaccin
hepat
b
haemophilu
influenza
type
b
exampl
hepat
b
innov
came
research
laboratori
chiron
corpor
succeed
make
hepat
b
surfac
antigen
yeast
thu
enabl
merck
glaxosmithklin
commerci
modern
hepat
b
vaccin
case
h
influenza
type
b
hib
praxi
biolog
connaught
laboratori
pioneer
develop
hib
polysaccharid
conjug
vaccin
compani
eventu
acquir
sanofi
wyethlederl
respect
greatest
contribut
biotechnolog
compani
introduct
multipl
idea
earli
vaccin
develop
test
determin
reject
carri
forward
small
compani
depend
sever
factor
success
vibrant
basic
research
environ
allow
creation
new
idea
environ
exist
wellfund
nih
academ
research
program
strong
ventur
capit
invest
commun
view
vaccin
compani
potenti
financi
reward
invest
opportun
strong
patent
law
provid
intellectu
properti
protect
essenti
commerci
success
fund
sourc
vaccin
r
includ
govern
profit
sale
product
risk
capit
charit
foundat
nih
compet
feder
agenc
program
taxpay
support
gener
success
similarli
vaccin
r
sponsor
dod
fda
cdc
usaid
competit
public
need
determin
execut
legisl
branch
govern
risk
capit
privat
investor
primari
sourc
fund
small
compani
investor
attract
potenti
profit
new
vaccin
forecast
determin
part
sale
current
vaccin
larg
vaccin
compani
divis
much
larger
pharmaceut
compani
seek
profit
sell
product
averag
pharmaceut
compani
reinvest
approxim
profit
product
sale
r
proport
appli
vaccin
sale
well
pharmaceut
product
pharmaceut
research
manufactur
associ
person
commun
vaccin
compani
subsidiari
larg
compani
vaccin
r
manufactur
must
compet
product
area
resourc
comparison
econom
vaccin
industri
pharmaceut
industri
europ
separ
unit
state
perform
mercer
consult
compani
fig
studi
unit
state
show
term
technic
feasibl
strong
patent
protect
potenti
market
size
taken
forward
develop
postphas
addit
candid
vaccin
might
licens
small
compani
even
largest
compani
product
develop
time
thu
gonogo
decis
must
made
market
size
major
determin
choic
two
candid
vaccin
otherwis
equal
technic
feasibl
likelihood
success
tabl
system
work
extrem
well
vaccin
larg
potenti
market
develop
world
technic
feasibl
demonstr
work
vaccin
diseas
exist
predominantli
poorer
region
world
eg
tb
work
imperfectli
diseas
develop
world
affect
rel
person
geograph
restrict
eg
lyme
diseas
diseas
limit
specif
risk
group
eg
cytomegaloviru
cmv
transplant
recipi
work
technic
feasibl
demonstr
eg
hiv
last
problem
solv
strong
basic
program
vaccinerel
scienc
particularli
hiv
staphylococcu
aureu
malaria
challeng
target
nich
vaccin
developedworld
market
much
attract
biotech
larg
pharmaceut
compani
evidenc
recent
biotech
vaccin
effort
west
nile
viru
japanes
enceph
viru
cmvtransplant
indic
dengu
involv
larg
compani
develop
manufactur
vaccin
meet
need
biodefens
health
need
poorer
countri
incent
must
establish
convinc
compani
develop
manufactur
product
incent
might
take
form
guarante
purchas
certain
volum
vaccin
specifi
standard
met
direct
contract
govern
agenc
publicli
fund
mechan
use
advanc
market
commit
creat
fund
mechan
vaccin
need
develop
world
endors
pilot
project
may
start
soon
solv
problem
high
technic
risk
opportun
cost
associ
vaccin
may
contribut
solut
combin
earli
invest
compani
may
will
engag
work
inde
may
alreadi
donat
sold
vaccin
low
price
poorer
countri
howev
practic
alon
solv
enorm
health
problem
worldwid
without
special
incent
unrealist
expect
compani
engag
r
diseas
predominantli
affect
poorer
region
world
manufactur
develop
countri
initi
india
china
recent
brazil
play
increas
role
meet
need
inde
alreadi
suppli
major
dose
older
vaccin
countri
expertis
capac
vaccin
r
increas
perhap
evolv
major
particip
suppli
new
vaccin
develop
world
numer
manufactur
emerg
countri
truli
stand
vaccin
industri
slowli
mushroom
india
sever
key
compani
emerg
includ
bharat
biotech
biolog
e
panacea
biotec
other
largest
one
privat
held
serum
institut
india
indian
vaccin
industri
significantli
benefit
technolog
transfer
west
despit
industri
success
avail
estim
suggest
r
spend
remain
rel
low
percentag
sale
serum
institut
india
world
largest
produc
vaccin
number
dose
produc
billion
dose
contribut
r
interest
tax
earn
expens
similar
two
industri
vs
respect
howev
expens
quit
differ
significantli
spent
product
distribut
includ
product
distribut
return
product
vaccin
industri
compar
pharmaceut
industri
wherea
pharmaceut
industri
spent
vaccin
industri
sale
market
administr
expens
vs
respect
consequ
within
compani
expect
salestoexpens
ratio
vaccin
similar
pharmaceut
product
revenu
increas
everi
year
although
increas
may
accomplish
sale
volum
price
stabil
vaccin
product
matur
increas
revenu
longer
possibl
henc
requir
steadi
rollout
new
product
howev
unlik
pharmaceut
old
vaccin
continu
profit
varieti
reason
includ
absenc
regulatori
pathway
gener
vaccin
deter
potenti
entrant
engag
complex
expens
approv
process
case
access
knowhow
proprietari
cell
line
viru
strain
intern
develop
process
far
valuabl
patent
protect
birth
cohort
renew
provid
ongo
unmet
need
vaccin
result
solesourc
vaccin
manufactur
fulli
depreci
asset
profit
pharmaceut
compani
one
exampl
mmr
vaccin
year
still
competit
unit
state
typic
vaccin
compani
sever
vaccin
candid
earli
develop
defin
r
phase
clinic
test
tabl
promis
tuberculosi
product
estim
higher
measl
vaccin
made
merck
glaxosmithklin
privat
held
vaccin
compani
relentlessli
invest
product
facilitiesinfrastructur
surpass
best
biotech
manufactur
facil
unit
state
power
growth
one
everi
two
children
immun
worldwid
get
least
one
vaccin
produc
serum
institut
vaccin
recent
develop
serum
institut
nasovac
live
attenu
trival
influenza
vaccin
menafrivac
meningococc
conjug
vaccin
pentavac
dtp
hepat
bhib
vaccin
inactiv
polio
vaccin
institut
continu
invest
r
current
work
rotaviru
vaccin
polyval
meningococc
conjug
vaccin
pneumococc
conjug
vaccin
hpv
vaccin
combin
vaccin
contain
acellular
pertussi
other
china
rank
world
largest
vaccin
consum
manufactur
countri
estim
annual
output
billion
dose
origin
six
governmentown
region
biolog
institut
part
china
nation
biotec
group
cnbg
consolid
china
nation
pharmaceut
group
corpor
sinopharm
group
co
ltd
cnbg
larg
r
center
beij
maxim
synergi
six
affili
institut
today
cnbg
sinopharm
suppli
dose
chines
nation
immun
program
vaccin
china
vaccin
manufactur
capabl
current
intens
focus
suppli
domest
need
pediatr
birth
cohort
million
newborn
annual
regist
vaccin
manufactur
china
licens
vaccin
sever
manufactur
member
develop
countri
vaccin
manufactur
network
dcvmn
world
health
organ
prequalifi
chinesemad
japanes
enceph
viru
vaccin
made
chengdu
institut
biolog
product
collabor
path
china
becam
first
countri
ever
year
product
use
countri
serum
institut
also
one
largest
supplier
measlescontain
vaccin
diphtheriatetanuspertussi
dtp
vaccin
un
agenc
unicef
pan
american
health
organ
paho
institut
make
measl
vaccin
cell
instead
chick
embryo
although
first
two
factor
consist
present
recent
year
downward
pressur
price
major
threat
current
compani
disincent
new
compani
freedom
price
vaccin
restrict
privat
market
less
vaccin
children
sold
unit
state
sold
privat
market
rest
sold
feder
state
govern
reduc
price
control
even
greater
western
europ
japan
intern
strong
downward
pressur
price
one
move
welldevelop
lessdevelop
region
world
addit
burden
partial
price
control
vaccin
industri
subject
intens
regul
sell
product
vaccin
facil
manufactur
approv
fda
regulatori
author
batch
must
releas
appropri
regulatori
agenc
usag
therefor
market
size
larg
determin
unit
state
cdc
europ
nation
regulatori
author
thu
vaccin
industri
oper
freemarket
environ
behavior
reflect
constraint
vaccin
busi
growth
futur
three
import
driver
new
vaccin
cmv
herp
simplex
viru
hsv
respiratori
syncyti
viru
rsv
noroviru
clostridium
difficil
enterotoxigen
escherichia
coli
etec
improv
influenza
other
gradual
shift
focal
point
immun
activ
pediatr
sector
adolesc
adult
sector
privat
market
expans
india
china
driven
highincom
famili
birth
cohort
million
million
respect
birth
cohort
roughli
equal
combin
birth
cohort
million
unit
state
europ
highand
even
middleincom
individu
shown
desir
abil
pay
vaccin
rel
high
price
relat
incom
countri
approv
hepat
e
vaccin
develop
xiamen
innovax
biotech
brazil
four
notabl
vaccin
manufactur
compani
biomanguinhosfiocruz
governmentown
entiti
suppli
full
demand
vaccin
brazilian
nation
immun
program
nip
also
r
collabor
glaxosmithklin
dengu
vaccin
butantan
institut
anoth
governmentown
institut
suppli
full
demand
smaller
number
vaccin
brazilian
nip
ataulfo
de
paiva
foundat
nonprofit
privat
institut
primarili
suppli
bcg
vaccin
brazilian
market
ezequiel
dia
foundat
fune
public
institut
part
mina
gerai
state
sinc
suppli
meningococc
conjug
vaccin
transfer
technolog
novarti
indian
vaccin
industri
advanc
among
three
develop
countri
alreadi
provid
signific
portion
world
vaccin
suppli
well
develop
new
vaccin
china
verg
transit
domesticonli
provid
vaccin
export
demonstr
solid
progress
vaccin
innov
brazil
approach
point
suppli
domest
need
larg
technolog
transfer
develop
world
togeth
emerg
player
middleincom
countri
increas
influenc
global
vaccin
industri
come
year
price
critic
compon
success
larg
compani
ventur
fund
small
compani
sinc
potenti
sale
determin
desir
invest
decis
public
expect
low
vaccin
price
although
chang
somewhat
recent
year
introduct
sever
new
higher
price
vaccin
varicella
rotaviru
pneumococc
conjug
vaccin
zoster
vaccin
hpv
vaccin
fig
larg
compani
believ
vaccin
price
accord
valu
societi
reduct
health
care
relat
cost
relief
pain
suffer
andor
prevent
death
reward
take
enorm
risk
inher
earli
vaccin
develop
price
far
exceed
manufactur
cost
essenti
produc
revenu
stream
allow
vaccin
competit
r
manufactur
resourc
within
larg
pharmaceut
compani
make
biotech
compani
attract
invest
opportun
gener
vaccin
price
declin
two
compani
compet
singl
vaccin
market
profit
fallen
sharpli
influenza
vaccin
market
highlight
cyclic
ebb
flow
competitor
recent
outbreak
shortag
lead
expand
competit
vaccin
surplu
follow
lower
price
vigor
largecompani
vaccin
industri
depend
upon
sever
factor
rich
research
environ
sponsor
larg
nih
mostli
carri
academia
sourc
new
creativ
idea
strong
patent
law
protect
intellectu
properti
freedom
price
product
fair
level
relat
valu
product
societi
wellimpl
immun
practic
us
vaccin
price
evolut
polio
vaccin
grow
develop
countri
altern
approach
local
product
explor
includ
access
bulk
inject
polio
vaccin
tech
transfer
big
pharma
part
strateg
allianc
develop
market
potenti
introduct
altern
inject
polio
vaccin
strain
sabin
strain
anoth
key
driver
expans
vaccin
market
india
china
brazil
vaccin
uptak
rate
india
china
brazil
still
low
compar
western
countri
eg
india
flu
vaccin
uptak
million
dose
vs
million
dose
unit
state
immun
rate
also
expect
increas
lowincom
countri
increas
vaccin
dose
requir
substanti
demand
lowincom
countri
expect
met
manufactur
dcvmn
network
dcvmn
expand
role
one
would
expect
signific
downward
pressur
vaccin
price
delic
balanc
innov
govern
support
industri
expertis
market
forc
led
establish
robust
vaccin
industri
continu
futur
industri
chang
howev
growth
new
market
emerg
economi
press
need
new
vaccin
develop
world
current
effort
pdp
public
creation
market
respons
need
success
lesson
learn
industri
vaccin
effort
incorpor
govern
philanthrop
driven
expect
estim
total
worldwid
vaccin
market
revenu
billion
top
four
western
supplier
see
tabl
account
approxim
sale
remaind
come
region
vaccin
compani
largest
locat
middleincom
countri
india
china
brazil
see
tabl
top
four
compani
slowli
lose
market
share
dose
dcvmn
sourc
dose
polio
erad
achiev
dose
share
drop
less
worldwid
dose
volum
come
year
erad
polio
becom
realiti
develop
countri
manufactur
phase
oral
polio
vaccin
product
howev
need
inactiv
polio
vaccin
grow
develop
countri
adopt
pediatr
immun
plan
demand
inject
